Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases, announced that the US Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's decision that Actavis infringed two Oxtellar XR Orange Book patents (US Patent Nos. 7,722,898 and 7,910,131) and that all three Oxtellar XR Orange Book patents (US Patent Nos. 7,722,898, 7,910,131 and 8,617,600) are valid.

"We are very pleased with the Appeals Court decision and continue to vigorously defend our intellectual property to provide our products with the protection they are entitled to," said Jack A. Khattar, president and CEO of Supernus. "This decision, following the New Jersey District Court's decision earlier in February this year, further substantiates Supernus' strong patents protecting Oxtellar XR."

Oxtellar XR is the first approved novel, oral once-daily extended release formulation of oxcarbazepine for the treatment of epilepsy. Oxtellar XR is an antiepileptic drug indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age. The product is available in 150mg, 300mg, and 600mg extended-release tablets.